Participated · Series B · Dec 2021

Redica Systems provides Quality and Regulatory Intelligence (QRI) solutions for life sciences organizations, centered on its Catalyst Platform and supplier data offerings. The Catalyst Platform is an enterprise AI regulatory and quality solution that integrates structured and unstructured data and includes capabilities such as Redica ID for entity resolution and Redica DocIQ for processing unstructured documents. The Redica Supplier Data Network (SDN) consolidates proprietary and public datasets to create secure, comprehensive supplier profiles and supports shared audit programs, GMP document repositories, and standardized questionnaires. Redica uses AI and human-in-the-loop workflows to deliver high data accuracy, actionable insights, and enterprise adoption. The company aggregates data from over 200 global regulators to power predictive quality, compliance, and supply chain oversight. Redica is headquartered in Pleasanton, California. Redica Systems provides a data analytics platform that aggregates complete data sets from health agencies and standards bodies into quality and regulatory intelligence. Its platform connects quality assurance and regulatory surveillance to help life sciences companies solve complex GxP compliance challenges. The company serves over 200 life science companies. Led by CEO Michale de la Torre, Redica aims to improve product quality and reduce compliance risk for its customers. The firm intends to use the financing to expand its product offerings. The company is based in Pleasanton, CA. Redica Systems provides a cloud-based quality and regulatory intelligence (QRI) platform for FDA-regulated industries, including pharmaceutical, medical device, and food companies. Its platform combines proprietary data sourcing and machine learning models with purpose-built visualizations to deliver actionable, high-quality data analytics and insights. The product enables quality and safety professionals to take a risk-based approach to decision making and regulatory compliance. Redica counts 19 of the top 20 pharma companies and 9 of the top 10 medical device firms as customers. The company plans to use new funding to extend its lead as a QRI platform, fuel product innovation, accelerate customer value, and expand its total addressable market. The announcement centers on a $30 million Series B financing led by Savant Growth with participation from Rock Creek Capital. Redica Systems offers a cloud-based regulatory and compliance platform that applies data, analytics and artificial intelligence to large and disparate government and customer datasets. Its quality and regulatory intelligence (QRI) platform delivers insights to quality and safety professionals to continuously improve compliance, reduce supplier risk, and increase team efficiency. The company serves over 200 customers across pharma, medical devices and food industries, including 19 of the top 20 pharma companies and 9 of the top 10 medical device companies. Founded in 2010 and headquartered in Pleasanton, CA, Redica combines subject-matter expertise with AI-driven data to simplify regulatory enforcement and compliance workflows. Leadership says the company is focused on using actionable data intelligence to reshape how organizations think about and manage regulatory compliance. The recent financing is intended to fund that strategic roadmap and support continued growth.

Participated · Series B · Nov 2021

PathologyWatch operates an end-to-end digital dermatopathology platform that integrates laboratory information systems, scanners, a digital viewer, and EMR reporting to give clinics 24/7 access to digital slides and expert dermatopathologists. The company’s core product streamlines workflows for dermatology clinics and labs, enabling faster diagnoses and broader insurance coverage. PathologyWatch is positioning its platform to improve access and equity in dermatopathology while reducing pathology costs. With the new funding, the company plans further research into skincare diagnostics and AI to enhance its diagnostic capabilities. PathologyWatch is expanding operations nationwide and will add new labs in Texas, Florida, and Arizona to support growing volume. CEO and cofounder Dan Lambert emphasizes the company’s role in digitally transforming dermatopathology and improving patient care. PathologyWatch is a Salt Lake City, UT‑based provider of digital dermatopathology services that offers fully interfaced EMR reporting and around‑the‑clock access to digital slides. The company’s solution gives dermatology clinics, hospitals and laboratories access to top‑tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR. PathologyWatch aims to improve operational efficiency by speeding up workflow and enhance patient outcomes via its expert professional team and partner laboratory services. Led by CEO and co‑founder Dan Lambert, the company has raised over $10M in total capital to date. PathologyWatch plans to use new funding to develop its digital dermatopathology offerings, scale its laboratory system and extend artificial intelligence research across various cancer lines to support larger clients and further technological progress. PathologyWatch builds intuitive, easy‑to‑implement digital dermatopathology solutions that digitize pathology workflows and provide EMR‑integrated reporting and 24/7 access to digital slides. The company offers access to top dermatopathologists and lets clients interpret and bill for cases, with a primary focus on outpatient clinics. PathologyWatch has deployed supervised AI in dermatopathology and reports a live clinical implementation in Australia that can generate full reports. It will use the Series A proceeds to strengthen outreach to dermatology clinics nationwide, including plans to triple its sales force over 12 months, expand marketing, and implement a channel partner strategy. The funding will also support continued development of technology and supervised AI for various cancer lines.

Led · Series A · Aug 2015

BoardVitals operates an online repository of thousands of practice questions and pre-selected tests based on actual medical board exams for students and doctors preparing for licensing. The service lets users refresh concepts or prepare for exams through practice tests and continually rated content. Co-founder Dan Lambert says the company is focused on building a new ecosystem for medical education; the platform receives hundreds of feedback notices every week to keep content up to date. The company has trained over 30,000 doctors and is used at about 150 institutions. BoardVitals aims to move medical board test prep — and ultimately basic medical education — to the web. BoardVitals.com operates a 24-hour physician board review question platform with specialty banks for practicing physicians, residents, and medical students in fields including psychiatry, pathology, emergency medicine, neurology, pediatrics, cardiology, family medicine, and surgery. The platform allows users to create customized practice tests and provides detailed up-to-date applications for each answer. Led by CEO Daniel Lambert and CMO Andrea Paul, the company said it will use new funding to further expand its question banks. Financially, the company announced a $500K seed financing to support that expansion. The reported seed backers remained unnamed. The company is NY-based and focused on delivering exam-preparation content to medical professionals.